M., Tietze, F
For weight management, GLP-1 receptor agonists (Wegovy, Saxenda) are only available through specialist NHS weight-management services after meeting specific BMI and comorbidity criteria, and following unsuccessful lifestyle interventions
In women, its levels drop at the beginning of menopause and remain lower after
CrossRef FOS drives podocyte injury and renal fibrosis in diabetic kidney disease via direct Smad3 binding Man Sun, Tianchi Yan, Wenjing Zhao, Zhifeng Cheng Cellular and Molecular Life Sciences.2026;[Epub] CrossRef Silencing of USP22 promotes FGF11 degradation to attenuates renal fibrosis in diabetic kidney disease Zhigang Wang, Chao Liu, Jing Lv, Jiping Sun, Xiaoyang Yu, Huixian Li Renal Failure.2026;[Epub] CrossRef Key module genes in proximal tubular cells drive microenvironmental chronic inflammation and fibrosis in diabetic kidney disease: A single-cell transcriptomic study Wenjing Zhou, Zhaogui Chen, Guanghui Ying, Li Liu, Wei Xiao, Jian Liu, Min Xia, Qiao Zhang, Xuelin He Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026
Just this week, Novo Nordisk rolled out its own weight-loss drug, Wegovy, in India, also in a pen-based format